Pfizer Q3 2026 earnings beat estimates, full-year outlook raised
Pfizer reported Q3 2026 revenue of $16.58B, down slightly YoY but up 7% excluding Comirnaty and Paxlovid. Full-year revenue guidance raised to $62B-$64B, with adjusted EPS of $2.95-$3.05. The outlook includes a $650M charge from an agreement with Innovent Biologics. Analysts expected lower revenue and EPS.
How this was made
The 30-second read
Why it matters
The earnings beat and raised guidance are likely to drive buying interest, especially after the market closed.
Market read
First‑report earnings with upgraded guidance for a large‑cap pharma, offering a clear trading catalyst.
What to watch
Potential headwinds from regulatory scrutiny of the Innovent deal could temper upside.
Background
Pfizer's Q3 2026 earnings were released, showing a modest revenue decline year‑over‑year but a strong operational growth rate and a higher full‑year outlook.
Ticker impact
Pfizer reported Q3 2026 revenue of $16.58 B and raised full‑year revenue guidance to $62‑64 B.
likely upward pressure as the market prices in the higher guidance
The beat on earnings and a 2‑3 B increase in revenue guidance are material for a large cap pharma, prompting traders to consider buying on any pull‑back.
Market effects
Boosts outlook for the broader pharma sector as peers may be re‑rated.
U.S. market may see a modest lift in healthcare indices.
Global investors track Pfizer's guidance for biotech and vaccine market sentiment.
Counterpoint
If the one‑time $650 M charge is fully priced in, the stock may face short‑term profit‑taking.
Key entities
- CompanyPfizer
Global pharmaceutical company reporting Q3 2026 results.
- CompanyInnovent Biologics
Partner in the in‑licensing and collaboration agreement that generated a $650 M charge.
